{ "format" : "linked-data-api", "version" : "0.2", "result" : {"_about" : "http://eldaddp.azurewebsites.net/answeredquestions.text?min-answer.dateOfAnswer=2014-10-29&min-answer.questionFirstMinisteriallyCorrected.=2014-10-28T16%3A37%3A54.0238756Z&max-answer.questionFirstMinisteriallyCorrected.=2014-11-13T10%3A22%3A56.0372213Z&max-answer.questionFirstAnswered.=2019-05-16T16%3A15%3A45Z", "definition" : "http://eldaddp.azurewebsites.net/meta/answeredquestions.text?min-answer.dateOfAnswer=2014-10-29&min-answer.questionFirstMinisteriallyCorrected.=2014-10-28T16%3A37%3A54.0238756Z&max-answer.questionFirstMinisteriallyCorrected.=2014-11-13T10%3A22%3A56.0372213Z&max-answer.questionFirstAnswered.=2019-05-16T16%3A15%3A45Z", "extendedMetadataVersion" : "http://eldaddp.azurewebsites.net/answeredquestions.text?min-answer.dateOfAnswer=2014-10-29&min-answer.questionFirstMinisteriallyCorrected.=2014-10-28T16%3A37%3A54.0238756Z&max-answer.questionFirstMinisteriallyCorrected.=2014-11-13T10%3A22%3A56.0372213Z&_metadata=all&max-answer.questionFirstAnswered.=2019-05-16T16%3A15%3A45Z", "first" : "http://eldaddp.azurewebsites.net/answeredquestions.text?min-answer.dateOfAnswer=2014-10-29&_page=0&min-answer.questionFirstMinisteriallyCorrected.=2014-10-28T16%3A37%3A54.0238756Z&max-answer.questionFirstMinisteriallyCorrected.=2014-11-13T10%3A22%3A56.0372213Z&max-answer.questionFirstAnswered.=2019-05-16T16%3A15%3A45Z", "hasPart" : "http://eldaddp.azurewebsites.net/answeredquestions.text?min-answer.dateOfAnswer=2014-10-29&min-answer.questionFirstMinisteriallyCorrected.=2014-10-28T16%3A37%3A54.0238756Z&max-answer.questionFirstMinisteriallyCorrected.=2014-11-13T10%3A22%3A56.0372213Z&max-answer.questionFirstAnswered.=2019-05-16T16%3A15%3A45Z", "isPartOf" : "http://eldaddp.azurewebsites.net/answeredquestions.text?min-answer.dateOfAnswer=2014-10-29&min-answer.questionFirstMinisteriallyCorrected.=2014-10-28T16%3A37%3A54.0238756Z&max-answer.questionFirstMinisteriallyCorrected.=2014-11-13T10%3A22%3A56.0372213Z&max-answer.questionFirstAnswered.=2019-05-16T16%3A15%3A45Z", "items" : [{"_about" : "http://data.parliament.uk/resources/105978", "AnsweringBody" : [{"_value" : "Department of Health"} ], "answer" : {"_about" : "http://data.parliament.uk/resources/105978/answer", "answerText" : {"_value" : "

The Civil Service Commission publish details of appointments made by exception and approved by them in their annual reports and on their website. These reports are available in the Library.<\/del><\/p>


It would not be appropriate to publish details of the requests turned down by the Commission as the numbers involved are small, and the individuals might be personally identified, directly or in combination with other published information.<\/del><\/p>

<\/p>

The Department does not operate an \u2018Instant Rewards\u2019 scheme. The Department does, however, operate an in-year bonus scheme, which has strict criteria, approval processes and budgetary control.<\/ins><\/p>

<\/p>"} , "answeringMember" : {"_about" : "http://data.parliament.uk/members/3932", "label" : {"_value" : "Biography information for Dr Dan Poulter"} } , "answeringMemberConstituency" : {"_value" : "Central Suffolk and North Ipswich"} , "answeringMemberPrinted" : {"_value" : "Dr Daniel Poulter"} , "dateOfAnswer" : {"_value" : "2014-11-10", "_datatype" : "dateTime"} , "isMinisterialCorrection" : {"_value" : "true", "_datatype" : "boolean"} , "previousAnswerVersion" : {"_about" : "http://data.parliament.uk/resources/105978/answer/previousversion/27280", "answeringMember" : {"_about" : "http://data.parliament.uk/members/3932", "label" : {"_value" : "Biography information for Dr Dan Poulter"} } , "answeringMemberConstituency" : {"_value" : "Central Suffolk and North Ipswich"} , "answeringMemberPrinted" : {"_value" : "Dr Daniel Poulter"} } , "questionFirstAnswered" : [{"_value" : "2014-11-10T16:58:06.487Z", "_datatype" : "dateTime"} ], "questionFirstMinisteriallyCorrected" : [{"_value" : "2014-11-10T17:38:55.2793146Z", "_datatype" : "dateTime"} ]} , "answeringDeptId" : {"_value" : "17"} , "answeringDeptShortName" : {"_value" : "Health"} , "answeringDeptSortName" : {"_value" : "Health"} , "date" : {"_value" : "2014-11-03", "_datatype" : "dateTime"} , "hansardHeading" : {"_value" : "Pay"} , "houseId" : {"_value" : "1"} , "legislature" : [{"_about" : "http://data.parliament.uk/terms/25259", "prefLabel" : {"_value" : "House of Commons"} } ], "questionText" : "To ask the Secretary of State for Health, how many Instant Rewards of what value were given to his Department's officials in (a) 2013 and (b) 2014 to date.", "registeredInterest" : {"_value" : "false", "_datatype" : "boolean"} , "tablingMember" : {"_about" : "http://data.parliament.uk/members/3917", "label" : {"_value" : "Biography information for Lord Walney"} } , "tablingMemberConstituency" : {"_value" : "Barrow and Furness"} , "tablingMemberPrinted" : [{"_value" : "John Woodcock"} ], "uin" : "213068"} , {"_about" : "http://data.parliament.uk/resources/101535", "AnsweringBody" : [{"_value" : "Department for Communities and Local Government"} ], "answer" : {"_about" : "http://data.parliament.uk/resources/101535/answer", "answerText" : {"_value" : "

Street lighting plays an important role in road safety, as well as ensuring the personal safety of pedestrians. I refer my Hon Friend to the answer of 13 May 2014, Official Report, columns 535-36W, which provides a comprehensive answer on how there is no prescriptive Whitehall guidance, and places in context the policy of the last Administration which actively encouraged cuts to street lighting.<\/ins><\/p>

<\/p>

<\/p>

Street lighting plays an important role in road safety, as well as ensuring the personal safety of pedestrians. There may be some roads where lights could be dimmed in the very early hours, saving taxpayers\u2019 money. However, this should be a local decision by elected local councillors, reflecting local circumstances-specially in relation to any concerns about crime. Equally, not every neighbourhood wants street lighting, as some communities, especially in rural areas, value dark skies.<\/del><\/p>

We believe that councils should listen to the views of their local residents, and then adopt appropriate local policies based on the neighbourhood, the precise location and the usage of the road/street. I previously noted that \u201cManual for Streets\u201d contains some useful guidance on getting the balance right when providing street lighting, taking into account the different issues around safety, crime prevention, street clutter and light pollution. Ultimately, there is no prescriptive Whitehall guidance, and any assessment will depend on local circumstances and local views.<\/del><\/p>

Notwithstanding, I would observe that Her Majesty\u2019s Opposition seem to have a short memory about their actions on cutting street lighting when they were in office:<\/del><\/p>

Department for Environment, Food and Rural Affairs<\/em>:<\/em><\/del><\/p>

The right hon. Member for Leeds Central (Hilary Benn) (now Shadow Secretary of State for Communities and Local Government) when Secretary of State for Environment, Food and Rural Affairs, his Department and its quangos lectured local councils to switch off or reduce street lighting to minimise carbon emissions. For example, in 2007, he personally launched the Carbon Trust Standard, which was tied to an extensive programme to reduce street lighting as part of the Local Authority Carbon Management Programme. As DEFRA Ministers told the House:<\/del><\/p>

\u201cAll authorities should be seeking to reduce energy usage both to cut costs and to help combat climate change. As street lighting accounts for a significant proportion of the energy used by authorities, it should be readily identified as an area that should be examined for potential efficiency savings\u201d<\/del><\/p>

(6 November 2006, Official Report<\/em>, column 709W).<\/del><\/p>

Department for Transport<\/em>:<\/em><\/del><\/p>

The Minister of State for Transport, the noble Lord Adonis (now a Shadow Treasury Minister) when asked about reducing the hours of operation of street lighting, noted that<\/del><\/p>

\u201cthe Government also support the Carbon Trust\u2019s local authority carbon management programme, which provides councils with support and guidance to help them realise carbon emissions savings from street lighting\u201d<\/del><\/p>

(17 December 2008, Official Report<\/em>, House of Lords<\/em>, column WA52). Transport Ministers also endorsed the Highways Agency\u2019s<\/del><\/p>

\u2018Efficiency Strategy for Road Lighting\u2019 which led to switching off motorway lighting at night (21 April 2008,<\/del><\/p>


Official Report, <\/em>column 1444W; Highways Agency<\/del><\/p>

\u201cEfficiency Strategy for Road Lighting Midnight Switch Off for Motorway Lighting\u201d, 2009).<\/del><\/p>

Department for Communities and Local Government<\/em>:<\/em><\/del><\/p>

The right hon. Member for Normanton, Pontefract and Castleford (Yvette Cooper) (now Shadow Home Secretary), when as Minister in the precursor Department to DCLG, noted there was nuanced debate on the extent of street lighting:<\/del><\/p>

\u201cWe all recognise the fact that there is a series of tensions around light pollution. People in the cities will never have the same view of the night sky as one can get in the middle of Dartmoor... There can be tensions too at neighbourhood level between the security-obsessed householder who has glaring white security lights stuck to every corner of the house, which flicker on every time a little bird flies past or the cat runs across the garden, and the neighbour who... has a telescope and cannot see across the garden, let alone into the skies\u201d<\/del><\/p>

(12 February 2004, Official Report<\/em>, column 510WH).<\/del><\/p>

Department <\/em>of<\/em> Energy and Climate Change<\/em>:<\/em><\/del><\/p>

In 2008, the right hon. Member for Leeds East (Hilary Benn) also personally launched the Carbon Reduction Commitment, which resulted in councils cutting carbon emissions from street lighting, including dimming or switching off lights. The Highway Agency\u2019s \u201cEnergy Strategy for Roadside Equipment\u201d (April 2010) explained that the approach of \u201cdimming, trimming and partial night lighting\u201d was a consequence of the requirements to meet the Carbon Reduction Commitment. As DECC Ministers said to the House:<\/del><\/p>

\u201cDECC is working to include street lighting in the Carbon Reduction Commitment. This will provide an incentive for local authorities to improve the energy efficiency of street lights. DECC is working closely with Communities and Local Government to develop the policy, in so far as it relates to local authorities\u201d<\/del><\/p>

(19 June 2009, Official Report<\/em>, column 515W). Of course, the Secretary of State for Energy and Climate Change at that time was the right hon. Member for Doncaster North (Edward Miliband) now Leader of HM Opposition.<\/del><\/p>

I hope this illuminates the historical fogginess of the Labour party\u2019s current campaign on municipal street lighting. I would suggest the last person out of Labour HQ tonight should turn off the lights.<\/del><\/p>

<\/p>"} , "answeringMember" : {"_about" : "http://data.parliament.uk/members/4043", "label" : {"_value" : "Biography information for Kris Hopkins"} } , "answeringMemberConstituency" : {"_value" : "Keighley"} , "answeringMemberPrinted" : {"_value" : "Kris Hopkins"} , "dateOfAnswer" : {"_value" : "2014-11-06", "_datatype" : "dateTime"} , "isMinisterialCorrection" : {"_value" : "true", "_datatype" : "boolean"} , "previousAnswerVersion" : {"_about" : "http://data.parliament.uk/resources/101535/answer/previousversion/26617", "answeringMember" : {"_about" : "http://data.parliament.uk/members/4043", "label" : {"_value" : "Biography information for Kris Hopkins"} } , "answeringMemberConstituency" : {"_value" : "Keighley"} , "answeringMemberPrinted" : {"_value" : "Kris Hopkins"} } , "questionFirstAnswered" : [{"_value" : "2014-11-06T17:31:07.79Z", "_datatype" : "dateTime"} ], "questionFirstMinisteriallyCorrected" : [{"_value" : "2014-11-10T17:19:10.1286961Z", "_datatype" : "dateTime"} ]} , "answeringDeptId" : {"_value" : "7"} , "answeringDeptShortName" : {"_value" : "Communities and Local Government"} , "answeringDeptSortName" : {"_value" : "Communities and Local Government"} , "date" : {"_value" : "2014-10-29", "_datatype" : "dateTime"} , "hansardHeading" : {"_value" : "Lighting"} , "houseId" : {"_value" : "1"} , "legislature" : [{"_about" : "http://data.parliament.uk/terms/25259", "prefLabel" : {"_value" : "House of Commons"} } ], "questionText" : "To ask the Secretary of State for Communities and Local Government, what guidance his Department has issued to local authorities on the level of street lighting they should have in place.", "registeredInterest" : {"_value" : "false", "_datatype" : "boolean"} , "tablingMember" : {"_about" : "http://data.parliament.uk/members/133", "label" : {"_value" : "Biography information for Mr David Ruffley"} } , "tablingMemberConstituency" : {"_value" : "Bury St Edmunds"} , "tablingMemberPrinted" : [{"_value" : "Mr David Ruffley"} ], "uin" : "212384"} , {"_about" : "http://data.parliament.uk/resources/101492", "AnsweringBody" : [{"_value" : "Ministry of Justice"} ], "answer" : {"_about" : "http://data.parliament.uk/resources/101492/answer", "answerText" : {"_value" : "

Security is paramount within prisons and it is important that the risk of any potential key compromise is addressed as quickly as possible in order to protect the public. When a key/lock incident is reported an immediate investigation is undertaken to assess the risk and unless it is clear that security has not been compromised, then locking mechanisms and keys will be replaced and/or other necessary remedial action will be taken.<\/p>

<\/p>

A range of procedural and physical measures are used to assist in the secure management of keys in prisons. These increasingly include electronic and biometric systems.<\/p>

<\/p>

The information requested is provided below.<\/p>

<\/p>

Table 1 - costs of partial/full relocking of prisons due to loss of keys from May 2010 - 29 October 2014:<\/p>

<\/p>

14/05/2010 Swaleside £95,430<\/p>

21/06/2010 Glen Parva £208,329<\/p>

04/11/2010 Warren Hill £101,301<\/p>

20/12/2010 Ashwell £15,576<\/p>

24/10/2011 Birmingham £499,000 (Paid for by G4S)<\/ins><\/p>

09/01/2012 Maidstone £5,847<\/p>

28/02/2014 Lindholme £40,286<\/p>

08/05/2014 Haverigg £32,882<\/p>

21/07/2014 Highpoint £14, 933<\/p>

<\/p>

Table 2 \u2013 number of reported incidents of lost keys from April 2010 \u2013 31 March 2014:<\/p>

<\/p>

2010/11 - 62<\/p>

2011/12 - 67<\/p>

2012/13 \u2013 73<\/p>

2013/14 \u2013 35 (* see note below)<\/p>

<\/p>

* Note: a change in the reporting requirements for key/lock incidents from April 2013 has resulted in a lower \u201clost keys\u201d figure for 2013/14 in comparison to the three previous years. In addition to keys \u201clost\u201d, the figures for the three previous years include keys inadvertently taken out of prisons and subsequently returned, but the figure for 2013/14 includes only keys lost, not those inadvertently taken out and returned.<\/p>

<\/p>

The figures quoted have been drawn from live administrative databases and may subsequently be amended. Due care is taken during processing and analysis, but the detail is subject to inaccuracies inherent in any large scale recording system.<\/em><\/p>"} , "answeringMember" : {"_about" : "http://data.parliament.uk/members/1453", "label" : {"_value" : "Biography information for Andrew Selous"} } , "answeringMemberConstituency" : {"_value" : "South West Bedfordshire"} , "answeringMemberPrinted" : {"_value" : "Andrew Selous"} , "dateOfAnswer" : {"_value" : "2014-11-03", "_datatype" : "dateTime"} , "isMinisterialCorrection" : {"_value" : "true", "_datatype" : "boolean"} , "previousAnswerVersion" : {"_about" : "http://data.parliament.uk/resources/101492/answer/previousversion/25520", "answeringMember" : {"_about" : "http://data.parliament.uk/members/1453", "label" : {"_value" : "Biography information for Andrew Selous"} } , "answeringMemberConstituency" : {"_value" : "South West Bedfordshire"} , "answeringMemberPrinted" : {"_value" : "Andrew Selous"} } , "questionFirstAnswered" : [{"_value" : "2014-11-03T11:21:01.633Z", "_datatype" : "dateTime"} ], "questionFirstMinisteriallyCorrected" : [{"_value" : "2014-11-03T17:23:08.2551012Z", "_datatype" : "dateTime"} ]} , "answeringDeptId" : {"_value" : "54"} , "answeringDeptShortName" : {"_value" : "Justice"} , "answeringDeptSortName" : {"_value" : "Justice"} , "date" : {"_value" : "2014-10-28", "_datatype" : "dateTime"} , "hansardHeading" : {"_value" : "Prisons: Locks and Keys"} , "houseId" : {"_value" : "1"} , "legislature" : [{"_about" : "http://data.parliament.uk/terms/25259", "prefLabel" : {"_value" : "House of Commons"} } ], "questionText" : "To ask the Secretary of State for Justice, how many incidents of lost keys have required the relocking of prisons since May 2010; and at what cost.", "registeredInterest" : {"_value" : "false", "_datatype" : "boolean"} , "tablingMember" : {"_about" : "http://data.parliament.uk/members/1577", "label" : {"_value" : "Biography information for Sadiq Khan"} } , "tablingMemberConstituency" : {"_value" : "Tooting"} , "tablingMemberPrinted" : [{"_value" : "Sadiq Khan"} ], "uin" : "212348"} , {"_about" : "http://data.parliament.uk/resources/101493", "AnsweringBody" : [{"_value" : "Ministry of Justice"} ], "answer" : {"_about" : "http://data.parliament.uk/resources/101493/answer", "answerText" : {"_value" : "

Security is paramount within prisons and it is important that the risk of any potential key compromise is addressed as quickly as possible in order to protect the public. When a key/lock incident is reported an immediate investigation is undertaken to assess the risk and unless it is clear that security has not been compromised, then locking mechanisms and keys will be replaced and/or other necessary remedial action will be taken.<\/p>

<\/p>

A range of procedural and physical measures are used to assist in the secure management of keys in prisons. These increasingly include electronic and biometric systems.<\/p>

<\/p>

The information requested is provided below.<\/p>

<\/p>

Table 1 - costs of partial/full relocking of prisons due to loss of keys from May 2010 - 29 October 2014:<\/p>

<\/p>

14/05/2010 Swaleside £95,430<\/p>

21/06/2010 Glen Parva £208,329<\/p>

04/11/2010 Warren Hill £101,301<\/p>

20/12/2010 Ashwell £15,576<\/p>

24/10/2011 Birmingham £499,000 (Paid for by G4S)<\/ins><\/p>

09/01/2012 Maidstone £5,847<\/p>

28/02/2014 Lindholme £40,286<\/p>

08/05/2014 Haverigg £32,882<\/p>

21/07/2014 Highpoint £14, 933<\/p>

<\/p>

Table 2 \u2013 number of reported incidents of lost keys from April 2010 \u2013 31 March 2014:<\/p>

<\/p>

2010/11 - 62<\/p>

2011/12 - 67<\/p>

2012/13 \u2013 73<\/p>

2013/14 \u2013 35 (* see note below)<\/p>

<\/p>

* Note: a change in the reporting requirements for key/lock incidents from April 2013 has resulted in a lower \u201clost keys\u201d figure for 2013/14 in comparison to the three previous years. In addition to keys \u201clost\u201d, the figures for the three previous years include keys inadvertently taken out of prisons and subsequently returned, but the figure for 2013/14 includes only keys lost, not those inadvertently taken out and returned.<\/p>

<\/p>

The figures quoted have been drawn from live administrative databases and may subsequently be amended. Due care is taken during processing and analysis, but the detail is subject to inaccuracies inherent in any large scale recording system.<\/em><\/p>"} , "answeringMember" : {"_about" : "http://data.parliament.uk/members/1453", "label" : {"_value" : "Biography information for Andrew Selous"} } , "answeringMemberConstituency" : {"_value" : "South West Bedfordshire"} , "answeringMemberPrinted" : {"_value" : "Andrew Selous"} , "dateOfAnswer" : {"_value" : "2014-11-03", "_datatype" : "dateTime"} , "isMinisterialCorrection" : {"_value" : "true", "_datatype" : "boolean"} , "previousAnswerVersion" : {"_about" : "http://data.parliament.uk/resources/101493/answer/previousversion/25521", "answeringMember" : {"_about" : "http://data.parliament.uk/members/1453", "label" : {"_value" : "Biography information for Andrew Selous"} } , "answeringMemberConstituency" : {"_value" : "South West Bedfordshire"} , "answeringMemberPrinted" : {"_value" : "Andrew Selous"} } , "questionFirstAnswered" : [{"_value" : "2014-11-03T11:21:01.78Z", "_datatype" : "dateTime"} ], "questionFirstMinisteriallyCorrected" : [{"_value" : "2014-11-03T17:29:21.2681994Z", "_datatype" : "dateTime"} ]} , "answeringDeptId" : {"_value" : "54"} , "answeringDeptShortName" : {"_value" : "Justice"} , "answeringDeptSortName" : {"_value" : "Justice"} , "date" : {"_value" : "2014-10-28", "_datatype" : "dateTime"} , "hansardHeading" : {"_value" : "Prisons: Locks and Keys"} , "houseId" : {"_value" : "1"} , "legislature" : [{"_about" : "http://data.parliament.uk/terms/25259", "prefLabel" : {"_value" : "House of Commons"} } ], "questionText" : "To ask the Secretary of State for Justice, how many incidents of lost keys there have been in prisons in each year since May 2010.", "registeredInterest" : {"_value" : "false", "_datatype" : "boolean"} , "tablingMember" : {"_about" : "http://data.parliament.uk/members/1577", "label" : {"_value" : "Biography information for Sadiq Khan"} } , "tablingMemberConstituency" : {"_value" : "Tooting"} , "tablingMemberPrinted" : [{"_value" : "Sadiq Khan"} ], "uin" : "212349"} , {"_about" : "http://data.parliament.uk/resources/100885", "AnsweringBody" : [{"_value" : "Department of Health"} ], "answer" : {"_about" : "http://data.parliament.uk/resources/100885/answer", "answerText" : {"_value" : "

The following table shows estimated expenditure on research on asthma, motor neurone disease (MND) and osteoporosis by the Medical Research Council, other Research Councils and Innovate UK, and by the National Institute for Health (NIHR) through its research programmes, research centres and units, and research fellowships.<\/p>

<\/p>

<\/p>

<\/p>

£ million<\/em><\/p>

<\/p>
<\/td>

2009-10<\/p><\/td>

2010-11<\/p><\/td>

2011-12<\/p><\/td>

2012-13<\/p><\/td>

2013-14<\/p><\/td><\/tr>

Asthma<\/p><\/td><\/tr>

Medical Research Council<\/p><\/td>

22.2 <\/del>6.6<\/ins><\/p><\/td>

17.5 <\/del>5.3<\/ins><\/p><\/td>

17.2<\/del> 4.5<\/ins><\/p><\/td>

19.4<\/del> 3.6<\/ins><\/p><\/td>

18.8<\/del> 5.4<\/ins><\/p><\/td><\/tr>

Other Research Councils and Innovate UK<\/p><\/td>

0.0<\/p><\/td>

0.1<\/p><\/td>

0.3<\/p><\/td>

1.5<\/p><\/td>

0.8<\/p><\/td><\/tr>

National Institute for Health Research<\/p><\/td>

2.6<\/p><\/td>

3.4<\/p><\/td>

2.4<\/p><\/td>

3.4<\/p><\/td>

3.8<\/p><\/td><\/tr>

Total<\/p><\/td>

24.8<\/del> 9.2<\/ins><\/p><\/td>

21.0<\/del> 8.8<\/ins><\/p><\/td>

19.9<\/del> 7.2<\/ins><\/p><\/td>

24.3 <\/del>8.5<\/ins><\/p><\/td>

23.4<\/del> 10.0<\/ins><\/p><\/td><\/tr>

Motor Neurone Research<\/p><\/td><\/tr>

Medical Research Council<\/p><\/td>

7.0<\/p><\/td>

7.5<\/p><\/td>

4.2<\/p><\/td>

4.1<\/p><\/td>

3.6<\/p><\/td><\/tr>

Other Research Councils and Innovate UK<\/p><\/td>

0.2<\/p><\/td>

0.2<\/p><\/td>

0.4<\/p><\/td>

0.7<\/p><\/td>

1.0<\/p><\/td><\/tr>

National Institute for Health Research<\/p><\/td>

0.1<\/p><\/td>

0.1<\/p><\/td>

0.4<\/p><\/td>

0.7<\/p><\/td>

0.5<\/p><\/td><\/tr>

Total<\/p><\/td>

7.3<\/p><\/td>

7.8<\/p><\/td>

5.0<\/p><\/td>

5.5<\/p><\/td>

5.1<\/p><\/td><\/tr>

Osteoporosis<\/p><\/td><\/tr>

Medical Research Council<\/p><\/td>

6.2<\/p><\/td>

5.4<\/p><\/td>

5.1<\/p><\/td>

4.6<\/p><\/td>

5.9<\/p><\/td><\/tr>

Other Research Councils and Innovate UK<\/p><\/td>

0.0<\/p><\/td>

0.0<\/p><\/td>

0.1<\/p><\/td>

0.4<\/p><\/td>

1.0<\/p><\/td><\/tr>

National Institute for Health Research<\/p><\/td>

0.3<\/p><\/td>

0.7<\/p><\/td>

0.8<\/p><\/td>

1.3<\/p><\/td>

1.8<\/p><\/td><\/tr>

Total<\/p><\/td>

6.5<\/p><\/td>

6.1<\/p><\/td>

6.0<\/p><\/td>

6.3<\/p><\/td>

8.7<\/p><\/td><\/tr><\/tbody><\/table>

<\/p>

<\/p>

<\/p>

The figures shown for asthma exclude research into air pollution and potential effects on health outcomes including asthma.<\/p>

<\/p>

<\/p>

<\/p>

Total spend by the NIHR on asthma, MND and osteoporosis is higher than the figures shown because expenditure by the NIHR Clinical Research Network (CRN) on these diseases cannot be disaggregated from total CRN expenditure. NIHR expenditure relating to development of new drugs for asthma, MND and osteroporosis occurs primarily through NIHR research infrastructure including the CRN and cannot be disaggregated from total expenditure.<\/p>

<\/p>

<\/p>

<\/p>

Information on MRC expenditure into the development of new drugs for asthma, MND or osteoporosis is not available.<\/p>

<\/p>"} , "answeringMember" : {"_about" : "http://data.parliament.uk/members/4020", "label" : {"_value" : "Biography information for George Freeman"} } , "answeringMemberConstituency" : {"_value" : "Mid Norfolk"} , "answeringMemberPrinted" : {"_value" : "George Freeman"} , "dateOfAnswer" : {"_value" : "2014-10-29", "_datatype" : "dateTime"} , "isMinisterialCorrection" : {"_value" : "true", "_datatype" : "boolean"} , "previousAnswerVersion" : {"_about" : "http://data.parliament.uk/resources/100885/answer/previousversion/25123", "answeringMember" : {"_about" : "http://data.parliament.uk/members/4020", "label" : {"_value" : "Biography information for George Freeman"} } , "answeringMemberConstituency" : {"_value" : "Mid Norfolk"} , "answeringMemberPrinted" : {"_value" : "George Freeman"} } , "questionFirstAnswered" : [{"_value" : "2014-10-29T17:12:29.113Z", "_datatype" : "dateTime"} ], "questionFirstMinisteriallyCorrected" : [{"_value" : "2014-11-13T10:22:56.0372213Z", "_datatype" : "dateTime"} ]} , "answeringDeptId" : {"_value" : "17"} , "answeringDeptShortName" : {"_value" : "Health"} , "answeringDeptSortName" : {"_value" : "Health"} , "date" : {"_value" : "2014-10-24", "_datatype" : "dateTime"} , "hansardHeading" : {"_value" : "Asthma: Drugs"} , "houseId" : {"_value" : "1"} , "legislature" : [{"_about" : "http://data.parliament.uk/terms/25259", "prefLabel" : {"_value" : "House of Commons"} } ], "questionText" : "To ask the Secretary of State for Health, how much the Government has spent on the development of new drugs to treat the symptoms of asthma in each of the last five years.", "registeredInterest" : {"_value" : "false", "_datatype" : "boolean"} , "tablingMember" : {"_about" : "http://data.parliament.uk/members/4026", "label" : {"_value" : "Biography information for Liz Kendall"} } , "tablingMemberConstituency" : {"_value" : "Leicester West"} , "tablingMemberPrinted" : [{"_value" : "Liz Kendall"} ], "uin" : "211885"} , {"_about" : "http://data.parliament.uk/resources/100887", "AnsweringBody" : [{"_value" : "Department of Health"} ], "answer" : {"_about" : "http://data.parliament.uk/resources/100887/answer", "answerText" : {"_value" : "

The following table shows estimated expenditure on research on asthma, motor neurone disease (MND) and osteoporosis by the Medical Research Council, other Research Councils and Innovate UK, and by the National Institute for Health (NIHR) through its research programmes, research centres and units, and research fellowships.<\/p>

<\/p>

<\/p>

<\/p>

£ million<\/em><\/p>

<\/p>
<\/td>

2009-10<\/p><\/td>

2010-11<\/p><\/td>

2011-12<\/p><\/td>

2012-13<\/p><\/td>

2013-14<\/p><\/td><\/tr>

Asthma<\/p><\/td><\/tr>

Medical Research Council<\/p><\/td>

22.2 <\/del>6.6<\/ins><\/p><\/td>

17.5 <\/del>5.3<\/ins><\/p><\/td>

17.2<\/del> 4.5<\/ins><\/p><\/td>

19.4<\/del> 3.6<\/ins><\/p><\/td>

18.8<\/del> 5.4<\/ins><\/p><\/td><\/tr>

Other Research Councils and Innovate UK<\/p><\/td>

0.0<\/p><\/td>

0.1<\/p><\/td>

0.3<\/p><\/td>

1.5<\/p><\/td>

0.8<\/p><\/td><\/tr>

National Institute for Health Research<\/p><\/td>

2.6<\/p><\/td>

3.4<\/p><\/td>

2.4<\/p><\/td>

3.4<\/p><\/td>

3.8<\/p><\/td><\/tr>

Total<\/p><\/td>

24.8<\/del> 9.2<\/ins><\/p><\/td>

21.0<\/del> 8.8<\/ins><\/p><\/td>

19.9<\/del> 7.2<\/ins><\/p><\/td>

24.3 <\/del>8.5<\/ins><\/p><\/td>

23.4<\/del> 10.0<\/ins><\/p><\/td><\/tr>

Motor Neurone Research<\/p><\/td><\/tr>

Medical Research Council<\/p><\/td>

7.0<\/p><\/td>

7.5<\/p><\/td>

4.2<\/p><\/td>

4.1<\/p><\/td>

3.6<\/p><\/td><\/tr>

Other Research Councils and Innovate UK<\/p><\/td>

0.2<\/p><\/td>

0.2<\/p><\/td>

0.4<\/p><\/td>

0.7<\/p><\/td>

1.0<\/p><\/td><\/tr>

National Institute for Health Research<\/p><\/td>

0.1<\/p><\/td>

0.1<\/p><\/td>

0.4<\/p><\/td>

0.7<\/p><\/td>

0.5<\/p><\/td><\/tr>

Total<\/p><\/td>

7.3<\/p><\/td>

7.8<\/p><\/td>

5.0<\/p><\/td>

5.5<\/p><\/td>

5.1<\/p><\/td><\/tr>

Osteoporosis<\/p><\/td><\/tr>

Medical Research Council<\/p><\/td>

6.2<\/p><\/td>

5.4<\/p><\/td>

5.1<\/p><\/td>

4.6<\/p><\/td>

5.9<\/p><\/td><\/tr>

Other Research Councils and Innovate UK<\/p><\/td>

0.0<\/p><\/td>

0.0<\/p><\/td>

0.1<\/p><\/td>

0.4<\/p><\/td>

1.0<\/p><\/td><\/tr>

National Institute for Health Research<\/p><\/td>

0.3<\/p><\/td>

0.7<\/p><\/td>

0.8<\/p><\/td>

1.3<\/p><\/td>

1.8<\/p><\/td><\/tr>

Total<\/p><\/td>

6.5<\/p><\/td>

6.1<\/p><\/td>

6.0<\/p><\/td>

6.3<\/p><\/td>

8.7<\/p><\/td><\/tr><\/tbody><\/table>

<\/p>

<\/p>

<\/p>

The figures shown for asthma exclude research into air pollution and potential effects on health outcomes including asthma.<\/p>

<\/p>

<\/p>

<\/p>

Total spend by the NIHR on asthma, MND and osteoporosis is higher than the figures shown because expenditure by the NIHR Clinical Research Network (CRN) on these diseases cannot be disaggregated from total CRN expenditure. NIHR expenditure relating to development of new drugs for asthma, MND and osteroporosis occurs primarily through NIHR research infrastructure including the CRN and cannot be disaggregated from total expenditure.<\/p>

<\/p>

<\/p>

<\/p>

Information on MRC expenditure into the development of new drugs for asthma, MND or osteoporosis is not available.<\/p>

<\/p>"} , "answeringMember" : {"_about" : "http://data.parliament.uk/members/4020", "label" : {"_value" : "Biography information for George Freeman"} } , "answeringMemberConstituency" : {"_value" : "Mid Norfolk"} , "answeringMemberPrinted" : {"_value" : "George Freeman"} , "dateOfAnswer" : {"_value" : "2014-10-29", "_datatype" : "dateTime"} , "isMinisterialCorrection" : {"_value" : "true", "_datatype" : "boolean"} , "previousAnswerVersion" : {"_about" : "http://data.parliament.uk/resources/100887/answer/previousversion/25123", "answeringMember" : {"_about" : "http://data.parliament.uk/members/4020", "label" : {"_value" : "Biography information for George Freeman"} } , "answeringMemberConstituency" : {"_value" : "Mid Norfolk"} , "answeringMemberPrinted" : {"_value" : "George Freeman"} } , "questionFirstAnswered" : [{"_value" : "2014-10-29T17:12:28.3318918Z", "_datatype" : "dateTime"} ], "questionFirstMinisteriallyCorrected" : [{"_value" : "2014-11-13T10:22:56.0372213Z", "_datatype" : "dateTime"} ]} , "answeringDeptId" : {"_value" : "17"} , "answeringDeptShortName" : {"_value" : "Health"} , "answeringDeptSortName" : {"_value" : "Health"} , "date" : {"_value" : "2014-10-24", "_datatype" : "dateTime"} , "hansardHeading" : {"_value" : "Asthma"} , "houseId" : {"_value" : "1"} , "legislature" : [{"_about" : "http://data.parliament.uk/terms/25259", "prefLabel" : {"_value" : "House of Commons"} } ], "questionText" : "To ask the Secretary of State for Health, how much public funding was allocated to research into asthma in each of the last five years.", "registeredInterest" : {"_value" : "false", "_datatype" : "boolean"} , "tablingMember" : {"_about" : "http://data.parliament.uk/members/4026", "label" : {"_value" : "Biography information for Liz Kendall"} } , "tablingMemberConstituency" : {"_value" : "Leicester West"} , "tablingMemberPrinted" : [{"_value" : "Liz Kendall"} ], "uin" : "211918"} , {"_about" : "http://data.parliament.uk/resources/100630", "AnsweringBody" : [{"_value" : "Department for Transport"} ], "answer" : {"_about" : "http://data.parliament.uk/resources/100630/answer", "answerText" : {"_value" : "

The case for improving inter-regional rail links in the North West of England has been assessed in a number of studies including the Northern Hub and Network Rail\u2019s Lancashire and Cumbria and North-West Route Utilisation strategies. The case will be further addressed in respect of Network Rail\u2019s Control Period 6 (2019-202<\/ins>1<\/del>4) and beyond through the Northern Route Study as part of Network Rail\u2019s Long Term Planning Process to inform decisions on the Government\u2019s Rail Investment Strategy for Control Period 6.<\/p>"} , "answeringMember" : {"_about" : "http://data.parliament.uk/members/1557", "label" : {"_value" : "Biography information for Baroness Kramer"} } , "answeringMemberPrinted" : {"_value" : "Baroness Kramer"} , "dateOfAnswer" : {"_value" : "2014-10-30", "_datatype" : "dateTime"} , "isMinisterialCorrection" : {"_value" : "true", "_datatype" : "boolean"} , "previousAnswerVersion" : {"_about" : "http://data.parliament.uk/resources/100630/answer/previousversion/25208", "answeringMember" : {"_about" : "http://data.parliament.uk/members/1557", "label" : {"_value" : "Biography information for Baroness Kramer"} } , "answeringMemberPrinted" : {"_value" : "Baroness Kramer"} } , "questionFirstAnswered" : [{"_value" : "2014-10-30T12:12:57.52Z", "_datatype" : "dateTime"} ], "questionFirstMinisteriallyCorrected" : [{"_value" : "2014-11-05T12:17:05.0180707Z", "_datatype" : "dateTime"} ]} , "answeringDeptId" : {"_value" : "27"} , "answeringDeptShortName" : {"_value" : "Transport"} , "answeringDeptSortName" : {"_value" : "Transport"} , "date" : {"_value" : "2014-10-23", "_datatype" : "dateTime"} , "hansardHeading" : {"_value" : "Railways: North West"} , "houseId" : {"_value" : "2"} , "legislature" : [{"_about" : "http://data.parliament.uk/terms/25277", "prefLabel" : {"_value" : "House of Lords"} } ], "questionText" : "To ask Her Majesty\u2019s Government what assessment they have made of the case for improving inter-regional rail links in the North West of England, particularly between East Lancashire and Greater Manchester.", "registeredInterest" : {"_value" : "false", "_datatype" : "boolean"} , "tablingMember" : {"_about" : "http://data.parliament.uk/members/2489", "label" : {"_value" : "Biography information for Baroness Massey of Darwen"} } , "tablingMemberPrinted" : [{"_value" : "Baroness Massey of Darwen"} ], "uin" : "HL2361"} , {"_about" : "http://data.parliament.uk/resources/100721", "AnsweringBody" : [{"_value" : "Department of Health"} ], "answer" : {"_about" : "http://data.parliament.uk/resources/100721/answer", "answerText" : {"_value" : "

The following table shows estimated expenditure on research on asthma, motor neurone disease (MND) and osteoporosis by the Medical Research Council, other Research Councils and Innovate UK, and by the National Institute for Health (NIHR) through its research programmes, research centres and units, and research fellowships.<\/p>

<\/p>

<\/p>

<\/p>

£ million<\/em><\/p>

<\/p>
<\/td>

2009-10<\/p><\/td>

2010-11<\/p><\/td>

2011-12<\/p><\/td>

2012-13<\/p><\/td>

2013-14<\/p><\/td><\/tr>

Asthma<\/p><\/td><\/tr>

Medical Research Council<\/p><\/td>

22.2 <\/del>6.6<\/ins><\/p><\/td>

17.5 <\/del>5.3<\/ins><\/p><\/td>

17.2<\/del> 4.5<\/ins><\/p><\/td>

19.4<\/del> 3.6<\/ins><\/p><\/td>

18.8<\/del> 5.4<\/ins><\/p><\/td><\/tr>

Other Research Councils and Innovate UK<\/p><\/td>

0.0<\/p><\/td>

0.1<\/p><\/td>

0.3<\/p><\/td>

1.5<\/p><\/td>

0.8<\/p><\/td><\/tr>

National Institute for Health Research<\/p><\/td>

2.6<\/p><\/td>

3.4<\/p><\/td>

2.4<\/p><\/td>

3.4<\/p><\/td>

3.8<\/p><\/td><\/tr>

Total<\/p><\/td>

24.8<\/del> 9.2<\/ins><\/p><\/td>

21.0<\/del> 8.8<\/ins><\/p><\/td>

19.9<\/del> 7.2<\/ins><\/p><\/td>

24.3 <\/del>8.5<\/ins><\/p><\/td>

23.4<\/del> 10.0<\/ins><\/p><\/td><\/tr>

Motor Neurone Research<\/p><\/td><\/tr>

Medical Research Council<\/p><\/td>

7.0<\/p><\/td>

7.5<\/p><\/td>

4.2<\/p><\/td>

4.1<\/p><\/td>

3.6<\/p><\/td><\/tr>

Other Research Councils and Innovate UK<\/p><\/td>

0.2<\/p><\/td>

0.2<\/p><\/td>

0.4<\/p><\/td>

0.7<\/p><\/td>

1.0<\/p><\/td><\/tr>

National Institute for Health Research<\/p><\/td>

0.1<\/p><\/td>

0.1<\/p><\/td>

0.4<\/p><\/td>

0.7<\/p><\/td>

0.5<\/p><\/td><\/tr>

Total<\/p><\/td>

7.3<\/p><\/td>

7.8<\/p><\/td>

5.0<\/p><\/td>

5.5<\/p><\/td>

5.1<\/p><\/td><\/tr>

Osteoporosis<\/p><\/td><\/tr>

Medical Research Council<\/p><\/td>

6.2<\/p><\/td>

5.4<\/p><\/td>

5.1<\/p><\/td>

4.6<\/p><\/td>

5.9<\/p><\/td><\/tr>

Other Research Councils and Innovate UK<\/p><\/td>

0.0<\/p><\/td>

0.0<\/p><\/td>

0.1<\/p><\/td>

0.4<\/p><\/td>

1.0<\/p><\/td><\/tr>

National Institute for Health Research<\/p><\/td>

0.3<\/p><\/td>

0.7<\/p><\/td>

0.8<\/p><\/td>

1.3<\/p><\/td>

1.8<\/p><\/td><\/tr>

Total<\/p><\/td>

6.5<\/p><\/td>

6.1<\/p><\/td>

6.0<\/p><\/td>

6.3<\/p><\/td>

8.7<\/p><\/td><\/tr><\/tbody><\/table>

<\/p>

<\/p>

<\/p>

The figures shown for asthma exclude research into air pollution and potential effects on health outcomes including asthma.<\/p>

<\/p>

<\/p>

<\/p>

Total spend by the NIHR on asthma, MND and osteoporosis is higher than the figures shown because expenditure by the NIHR Clinical Research Network (CRN) on these diseases cannot be disaggregated from total CRN expenditure. NIHR expenditure relating to development of new drugs for asthma, MND and osteroporosis occurs primarily through NIHR research infrastructure including the CRN and cannot be disaggregated from total expenditure.<\/p>

<\/p>

<\/p>

<\/p>

Information on MRC expenditure into the development of new drugs for asthma, MND or osteoporosis is not available.<\/p>

<\/p>"} , "answeringMember" : {"_about" : "http://data.parliament.uk/members/4020", "label" : {"_value" : "Biography information for George Freeman"} } , "answeringMemberConstituency" : {"_value" : "Mid Norfolk"} , "answeringMemberPrinted" : {"_value" : "George Freeman"} , "dateOfAnswer" : {"_value" : "2014-10-29", "_datatype" : "dateTime"} , "isMinisterialCorrection" : {"_value" : "true", "_datatype" : "boolean"} , "previousAnswerVersion" : {"_about" : "http://data.parliament.uk/resources/100721/answer/previousversion/25123", "answeringMember" : {"_about" : "http://data.parliament.uk/members/4020", "label" : {"_value" : "Biography information for George Freeman"} } , "answeringMemberConstituency" : {"_value" : "Mid Norfolk"} , "answeringMemberPrinted" : {"_value" : "George Freeman"} } , "questionFirstAnswered" : [{"_value" : "2014-10-29T17:12:28.3318918Z", "_datatype" : "dateTime"} ], "questionFirstMinisteriallyCorrected" : [{"_value" : "2014-11-13T10:22:56.0372213Z", "_datatype" : "dateTime"} ]} , "answeringDeptId" : {"_value" : "17"} , "answeringDeptShortName" : {"_value" : "Health"} , "answeringDeptSortName" : {"_value" : "Health"} , "date" : {"_value" : "2014-10-23", "_datatype" : "dateTime"} , "hansardHeading" : {"_value" : "Osteoporosis"} , "houseId" : {"_value" : "1"} , "legislature" : [{"_about" : "http://data.parliament.uk/terms/25259", "prefLabel" : {"_value" : "House of Commons"} } ], "questionText" : "To ask the Secretary of State for Health, how much from the publich purse has been spent on research into osteoporosis in each of the last five years.", "registeredInterest" : {"_value" : "false", "_datatype" : "boolean"} , "tablingMember" : {"_about" : "http://data.parliament.uk/members/4026", "label" : {"_value" : "Biography information for Liz Kendall"} } , "tablingMemberConstituency" : {"_value" : "Leicester West"} , "tablingMemberPrinted" : [{"_value" : "Liz Kendall"} ], "uin" : "211732"} , {"_about" : "http://data.parliament.uk/resources/100723", "AnsweringBody" : [{"_value" : "Department of Health"} ], "answer" : {"_about" : "http://data.parliament.uk/resources/100723/answer", "answerText" : {"_value" : "

The following table shows estimated expenditure on research on asthma, motor neurone disease (MND) and osteoporosis by the Medical Research Council, other Research Councils and Innovate UK, and by the National Institute for Health (NIHR) through its research programmes, research centres and units, and research fellowships.<\/p>

<\/p>

<\/p>

<\/p>

£ million<\/em><\/p>

<\/p>
<\/td>

2009-10<\/p><\/td>

2010-11<\/p><\/td>

2011-12<\/p><\/td>

2012-13<\/p><\/td>

2013-14<\/p><\/td><\/tr>

Asthma<\/p><\/td><\/tr>

Medical Research Council<\/p><\/td>

22.2 <\/del>6.6<\/ins><\/p><\/td>

17.5 <\/del>5.3<\/ins><\/p><\/td>

17.2<\/del> 4.5<\/ins><\/p><\/td>

19.4<\/del> 3.6<\/ins><\/p><\/td>

18.8<\/del> 5.4<\/ins><\/p><\/td><\/tr>

Other Research Councils and Innovate UK<\/p><\/td>

0.0<\/p><\/td>

0.1<\/p><\/td>

0.3<\/p><\/td>

1.5<\/p><\/td>

0.8<\/p><\/td><\/tr>

National Institute for Health Research<\/p><\/td>

2.6<\/p><\/td>

3.4<\/p><\/td>

2.4<\/p><\/td>

3.4<\/p><\/td>

3.8<\/p><\/td><\/tr>

Total<\/p><\/td>

24.8<\/del> 9.2<\/ins><\/p><\/td>

21.0<\/del> 8.8<\/ins><\/p><\/td>

19.9<\/del> 7.2<\/ins><\/p><\/td>

24.3 <\/del>8.5<\/ins><\/p><\/td>

23.4<\/del> 10.0<\/ins><\/p><\/td><\/tr>

Motor Neurone Research<\/p><\/td><\/tr>

Medical Research Council<\/p><\/td>

7.0<\/p><\/td>

7.5<\/p><\/td>

4.2<\/p><\/td>

4.1<\/p><\/td>

3.6<\/p><\/td><\/tr>

Other Research Councils and Innovate UK<\/p><\/td>

0.2<\/p><\/td>

0.2<\/p><\/td>

0.4<\/p><\/td>

0.7<\/p><\/td>

1.0<\/p><\/td><\/tr>

National Institute for Health Research<\/p><\/td>

0.1<\/p><\/td>

0.1<\/p><\/td>

0.4<\/p><\/td>

0.7<\/p><\/td>

0.5<\/p><\/td><\/tr>

Total<\/p><\/td>

7.3<\/p><\/td>

7.8<\/p><\/td>

5.0<\/p><\/td>

5.5<\/p><\/td>

5.1<\/p><\/td><\/tr>

Osteoporosis<\/p><\/td><\/tr>

Medical Research Council<\/p><\/td>

6.2<\/p><\/td>

5.4<\/p><\/td>

5.1<\/p><\/td>

4.6<\/p><\/td>

5.9<\/p><\/td><\/tr>

Other Research Councils and Innovate UK<\/p><\/td>

0.0<\/p><\/td>

0.0<\/p><\/td>

0.1<\/p><\/td>

0.4<\/p><\/td>

1.0<\/p><\/td><\/tr>

National Institute for Health Research<\/p><\/td>

0.3<\/p><\/td>

0.7<\/p><\/td>

0.8<\/p><\/td>

1.3<\/p><\/td>

1.8<\/p><\/td><\/tr>

Total<\/p><\/td>

6.5<\/p><\/td>

6.1<\/p><\/td>

6.0<\/p><\/td>

6.3<\/p><\/td>

8.7<\/p><\/td><\/tr><\/tbody><\/table>

<\/p>

<\/p>

<\/p>

The figures shown for asthma exclude research into air pollution and potential effects on health outcomes including asthma.<\/p>

<\/p>

<\/p>

<\/p>

Total spend by the NIHR on asthma, MND and osteoporosis is higher than the figures shown because expenditure by the NIHR Clinical Research Network (CRN) on these diseases cannot be disaggregated from total CRN expenditure. NIHR expenditure relating to development of new drugs for asthma, MND and osteroporosis occurs primarily through NIHR research infrastructure including the CRN and cannot be disaggregated from total expenditure.<\/p>

<\/p>

<\/p>

<\/p>

Information on MRC expenditure into the development of new drugs for asthma, MND or osteoporosis is not available.<\/p>

<\/p>"} , "answeringMember" : {"_about" : "http://data.parliament.uk/members/4020", "label" : {"_value" : "Biography information for George Freeman"} } , "answeringMemberConstituency" : {"_value" : "Mid Norfolk"} , "answeringMemberPrinted" : {"_value" : "George Freeman"} , "dateOfAnswer" : {"_value" : "2014-10-29", "_datatype" : "dateTime"} , "isMinisterialCorrection" : {"_value" : "true", "_datatype" : "boolean"} , "previousAnswerVersion" : {"_about" : "http://data.parliament.uk/resources/100723/answer/previousversion/25123", "answeringMember" : {"_about" : "http://data.parliament.uk/members/4020", "label" : {"_value" : "Biography information for George Freeman"} } , "answeringMemberConstituency" : {"_value" : "Mid Norfolk"} , "answeringMemberPrinted" : {"_value" : "George Freeman"} } , "questionFirstAnswered" : [{"_value" : "2014-10-29T17:12:28.3318918Z", "_datatype" : "dateTime"} ], "questionFirstMinisteriallyCorrected" : [{"_value" : "2014-11-13T10:22:56.0372213Z", "_datatype" : "dateTime"} ]} , "answeringDeptId" : {"_value" : "17"} , "answeringDeptShortName" : {"_value" : "Health"} , "answeringDeptSortName" : {"_value" : "Health"} , "date" : {"_value" : "2014-10-23", "_datatype" : "dateTime"} , "hansardHeading" : {"_value" : "Motor Neurone Disease: Drugs"} , "houseId" : {"_value" : "1"} , "legislature" : [{"_about" : "http://data.parliament.uk/terms/25259", "prefLabel" : {"_value" : "House of Commons"} } ], "questionText" : "To ask the Secretary of State for Health, how much from the public purse has been spent on the development of new drugs to prevent or treat symptoms of motore neurone disease in each of the last five years.", "registeredInterest" : {"_value" : "false", "_datatype" : "boolean"} , "tablingMember" : {"_about" : "http://data.parliament.uk/members/4026", "label" : {"_value" : "Biography information for Liz Kendall"} } , "tablingMemberConstituency" : {"_value" : "Leicester West"} , "tablingMemberPrinted" : [{"_value" : "Liz Kendall"} ], "uin" : "211734"} , {"_about" : "http://data.parliament.uk/resources/100728", "AnsweringBody" : [{"_value" : "Department of Health"} ], "answer" : {"_about" : "http://data.parliament.uk/resources/100728/answer", "answerText" : {"_value" : "

The following table shows estimated expenditure on research on asthma, motor neurone disease (MND) and osteoporosis by the Medical Research Council, other Research Councils and Innovate UK, and by the National Institute for Health (NIHR) through its research programmes, research centres and units, and research fellowships.<\/p>

<\/p>

<\/p>

<\/p>

£ million<\/em><\/p>

<\/p>
<\/td>

2009-10<\/p><\/td>

2010-11<\/p><\/td>

2011-12<\/p><\/td>

2012-13<\/p><\/td>

2013-14<\/p><\/td><\/tr>

Asthma<\/p><\/td><\/tr>

Medical Research Council<\/p><\/td>

22.2 <\/del>6.6<\/ins><\/p><\/td>

17.5 <\/del>5.3<\/ins><\/p><\/td>

17.2<\/del> 4.5<\/ins><\/p><\/td>

19.4<\/del> 3.6<\/ins><\/p><\/td>

18.8<\/del> 5.4<\/ins><\/p><\/td><\/tr>

Other Research Councils and Innovate UK<\/p><\/td>

0.0<\/p><\/td>

0.1<\/p><\/td>

0.3<\/p><\/td>

1.5<\/p><\/td>

0.8<\/p><\/td><\/tr>

National Institute for Health Research<\/p><\/td>

2.6<\/p><\/td>

3.4<\/p><\/td>

2.4<\/p><\/td>

3.4<\/p><\/td>

3.8<\/p><\/td><\/tr>

Total<\/p><\/td>

24.8<\/del> 9.2<\/ins><\/p><\/td>

21.0<\/del> 8.8<\/ins><\/p><\/td>

19.9<\/del> 7.2<\/ins><\/p><\/td>

24.3 <\/del>8.5<\/ins><\/p><\/td>

23.4<\/del> 10.0<\/ins><\/p><\/td><\/tr>

Motor Neurone Research<\/p><\/td><\/tr>

Medical Research Council<\/p><\/td>

7.0<\/p><\/td>

7.5<\/p><\/td>

4.2<\/p><\/td>

4.1<\/p><\/td>

3.6<\/p><\/td><\/tr>

Other Research Councils and Innovate UK<\/p><\/td>

0.2<\/p><\/td>

0.2<\/p><\/td>

0.4<\/p><\/td>

0.7<\/p><\/td>

1.0<\/p><\/td><\/tr>

National Institute for Health Research<\/p><\/td>

0.1<\/p><\/td>

0.1<\/p><\/td>

0.4<\/p><\/td>

0.7<\/p><\/td>

0.5<\/p><\/td><\/tr>

Total<\/p><\/td>

7.3<\/p><\/td>

7.8<\/p><\/td>

5.0<\/p><\/td>

5.5<\/p><\/td>

5.1<\/p><\/td><\/tr>

Osteoporosis<\/p><\/td><\/tr>

Medical Research Council<\/p><\/td>

6.2<\/p><\/td>

5.4<\/p><\/td>

5.1<\/p><\/td>

4.6<\/p><\/td>

5.9<\/p><\/td><\/tr>

Other Research Councils and Innovate UK<\/p><\/td>

0.0<\/p><\/td>

0.0<\/p><\/td>

0.1<\/p><\/td>

0.4<\/p><\/td>

1.0<\/p><\/td><\/tr>

National Institute for Health Research<\/p><\/td>

0.3<\/p><\/td>

0.7<\/p><\/td>

0.8<\/p><\/td>

1.3<\/p><\/td>

1.8<\/p><\/td><\/tr>

Total<\/p><\/td>

6.5<\/p><\/td>

6.1<\/p><\/td>

6.0<\/p><\/td>

6.3<\/p><\/td>

8.7<\/p><\/td><\/tr><\/tbody><\/table>

<\/p>

<\/p>

<\/p>

The figures shown for asthma exclude research into air pollution and potential effects on health outcomes including asthma.<\/p>

<\/p>

<\/p>

<\/p>

Total spend by the NIHR on asthma, MND and osteoporosis is higher than the figures shown because expenditure by the NIHR Clinical Research Network (CRN) on these diseases cannot be disaggregated from total CRN expenditure. NIHR expenditure relating to development of new drugs for asthma, MND and osteroporosis occurs primarily through NIHR research infrastructure including the CRN and cannot be disaggregated from total expenditure.<\/p>

<\/p>

<\/p>

<\/p>

Information on MRC expenditure into the development of new drugs for asthma, MND or osteoporosis is not available.<\/p>

<\/p>"} , "answeringMember" : {"_about" : "http://data.parliament.uk/members/4020", "label" : {"_value" : "Biography information for George Freeman"} } , "answeringMemberConstituency" : {"_value" : "Mid Norfolk"} , "answeringMemberPrinted" : {"_value" : "George Freeman"} , "dateOfAnswer" : {"_value" : "2014-10-29", "_datatype" : "dateTime"} , "isMinisterialCorrection" : {"_value" : "true", "_datatype" : "boolean"} , "previousAnswerVersion" : {"_about" : "http://data.parliament.uk/resources/100728/answer/previousversion/25123", "answeringMember" : {"_about" : "http://data.parliament.uk/members/4020", "label" : {"_value" : "Biography information for George Freeman"} } , "answeringMemberConstituency" : {"_value" : "Mid Norfolk"} , "answeringMemberPrinted" : {"_value" : "George Freeman"} } , "questionFirstAnswered" : [{"_value" : "2014-10-29T17:12:28.3318918Z", "_datatype" : "dateTime"} ], "questionFirstMinisteriallyCorrected" : [{"_value" : "2014-11-13T10:22:56.0372213Z", "_datatype" : "dateTime"} ]} , "answeringDeptId" : {"_value" : "17"} , "answeringDeptShortName" : {"_value" : "Health"} , "answeringDeptSortName" : {"_value" : "Health"} , "date" : {"_value" : "2014-10-23", "_datatype" : "dateTime"} , "hansardHeading" : {"_value" : "Motor Neurone Disease"} , "houseId" : {"_value" : "1"} , "legislature" : [{"_about" : "http://data.parliament.uk/terms/25259", "prefLabel" : {"_value" : "House of Commons"} } ], "questionText" : "To ask the Secretary of State for Health, how much from the public purse has been spent on research into motor neurone disease in each of the last five years.", "registeredInterest" : {"_value" : "false", "_datatype" : "boolean"} , "tablingMember" : {"_about" : "http://data.parliament.uk/members/4026", "label" : {"_value" : "Biography information for Liz Kendall"} } , "tablingMemberConstituency" : {"_value" : "Leicester West"} , "tablingMemberPrinted" : [{"_value" : "Liz Kendall"} ], "uin" : "211730"} ], "itemsPerPage" : 10, "next" : "http://eldaddp.azurewebsites.net/answeredquestions.text?min-answer.dateOfAnswer=2014-10-29&_page=1&min-answer.questionFirstMinisteriallyCorrected.=2014-10-28T16%3A37%3A54.0238756Z&max-answer.questionFirstMinisteriallyCorrected.=2014-11-13T10%3A22%3A56.0372213Z&max-answer.questionFirstAnswered.=2019-05-16T16%3A15%3A45Z", "page" : 0, "startIndex" : 1, "totalResults" : 11, "type" : ["http://purl.org/linked-data/api/vocab#ListEndpoint", "http://purl.org/linked-data/api/vocab#Page"]} }